- Progen Pharmaceuticals' (PGLA) candidate for the adjuvant treatment of hepatocellular carcinoma after surgical resection, PI-88, failed to achieve its primary endpoint of Disease Free Survival (DFS) in a Phase 3 trial conducted by licensee Medigan Biotechnology Corp. The results are from an interim analysis of data from 131 patients. Further analysis will be conducted by an independent committee.
- Medigan licensed PI-88 in 2010.
- No premarket trades of PGLA shares have been recorded according to NASDAQ.